Literature DB >> 29407721

Comparison of residual depressive symptoms and functional impairment between fully and partially remitted patients with major depressive disorder: a multicenter study.

Le Xiao1, Lei Feng1, Xue-Quan Zhu1, Yuan Feng1, Wen-Yuan Wu2, Gabor S Ungvari3, Chee H Ng4, Yu-Tao Xiang5, Gang Wang6.   

Abstract

This study compared residual depressive and somatic symptoms and functional impairment between remitted and partially remitted patients with major depressive disorder (MDD), and explored the associations of functioning with demographic and clinical characteristics including residual depressive symptoms. Altogether, 1503 outpatients with MDD formed the study sample. Residual symptoms and psychosocial functioning were measured using standardized instruments. Approximately half (51.2%) of the patients who responded to antidepressant treatment achieved remission ('remitters'), while the rest who responded to treatment achieved only partial remission ('non-remitters'). Residual mood symptoms in remitters included sleep disturbances (66.6%), fatigue (32.3%), decreased concentration (31.3%), appetite/weight disturbances (28.8%), psychomotor changes (23.2%), sad mood (21.9%) and loss of interest (21.1%) measured by the Quick Inventory of Depressive Symptomatology-Self-Report. Residual somatic symptoms included headache (31.9%), intestinal complaints (31.3%), heart pounding/racing (26.3%), gastric complaints (22.3%), dizziness (22.2%) and stomach pain (20.6%) measured by the Patient Health Questionnaire-15. Such residual symptoms were even more frequent in the 'non-remitters' group. Residual symptoms of fatigue, psychomotor changes, sleep disturbance and appetite/weight disturbance contributed to impairment of all functional domains. Given the negative impact of residual symptoms on psychosocial functioning, more attention needs to be paid to the assessment and treatment of residual depressive symptoms.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Functioning; Major depressive disorder; Remission; Residual symptoms; Treatment response

Mesh:

Substances:

Year:  2018        PMID: 29407721     DOI: 10.1016/j.psychres.2018.01.020

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  10 in total

Review 1.  Effectiveness of Pharmacotherapy for Depression after Adult Traumatic Brain Injury: an Umbrella Review.

Authors:  Amelia J Hicks; Fiona J Clay; Amelia C James; Malcolm Hopwood; Jennie L Ponsford
Journal:  Neuropsychol Rev       Date:  2022-06-14       Impact factor: 7.444

2.  In pursuit of full recovery in major depressive disorder.

Authors:  Vicent-Gil M; Serra-Blasco M; Navarra-Ventura G; Trujols J; Balanzá-Martínez V; Portella Mj; Cardoner N
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2022-09-09       Impact factor: 5.760

3.  Assessing the psychometric properties of the PROMIS sleep measures in persons with psychosis.

Authors:  Christina L G Savage; Ryan D Orth; Anyela M Jacome; Melanie E Bennett; Jack J Blanchard
Journal:  Sleep       Date:  2021-11-12       Impact factor: 6.313

4.  Psychiatric Symptom Profiles Predict Functional Impairment.

Authors:  Joachim Tanner; Thomas Zeffiro; Daniela Wyss; Noelle Perron; Michel Rufer; Christoph Mueller-Pfeiffer
Journal:  Front Psychiatry       Date:  2019-02-13       Impact factor: 4.157

5.  Direct sunlight exposure reduces hair cortisol levels in rhesus monkeys (Macaca mulatta).

Authors:  Xiao-Li Feng; He-Long Che; Xi Ning; Xue-Ying Ba; Juan Li; Jing-Fang Zhang; Yun Wang; Zheng-Fei Hu; Xin-Tian Hu; Xiao-Feng Ren
Journal:  Zool Res       Date:  2019-11-18

6.  The neuroprogressive nature of major depressive disorder: evidence from an intrinsic connectome analysis.

Authors:  Jin Liu; Yiming Fan; Bangshan Liu; Yumeng Ju; Mi Wang; Qiangli Dong; Xiaowen Lu; Jinrong Sun; Liang Zhang; Hua Guo; Li Zhang; Zexuan Li; Mei Liao; Yan Zhang; Dewen Hu; Lingjiang Li
Journal:  Transl Psychiatry       Date:  2021-02-04       Impact factor: 6.222

7.  Additional Reduction of Residual Symptoms with Aripiprazole Augmentation in the Patients with Partially Remitted Major Depressive Disorder.

Authors:  Cheolmin Shin; Chi-Un Pae; Kyung Phil Kwak; Sang Won Jeon; Hyun-Ghang Jeong; Jong-Woo Kim; Youn Jung Lee; Ashwin A Patkar; Changsu Han
Journal:  Clin Psychopharmacol Neurosci       Date:  2021-05-31       Impact factor: 2.582

8.  Humanistic and economic burden associated with depression in the United States: a cross-sectional survey analysis.

Authors:  Saundra Jain; Shaloo Gupta; Vicky W Li; Ellison Suthoff; Alix Arnaud
Journal:  BMC Psychiatry       Date:  2022-08-11       Impact factor: 4.144

9.  Factors associated with antipsychotic use in non-psychotic depressed patients: results from a clinical multicenter survey.

Authors:  Jingjing Zhou; Tong Zhu; Xuequan Zhu; Britta Galling; Le Xiao
Journal:  BMC Psychiatry       Date:  2022-02-03       Impact factor: 3.630

10.  Mindfulness-Based Cognitive Therapy in Recurrent MDD Patients With Residual Symptoms: Alterations in Resting-State Theta Oscillation Dynamics Associated With Changes in Depression and Rumination.

Authors:  Jing Wang; Feng Ren; Bingling Gao; Xin Yu
Journal:  Front Psychiatry       Date:  2022-03-07       Impact factor: 4.157

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.